Short Squeeze Setup — velZ +0.68 · age 102w×0.45 · 16.58%
Founder-Led — founder/CEO led
Earnings Tailwind — ER in 20.09d · w1 med 1.0% (mag 1/3) · winRate 50.0% (rel 0/3) · n28
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacte… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: October 25, 2019
Headquarters: 100 Campus Drive, Florham Park, NJ, United States, 07932
Founder-Led: Yes — Tadataka Yamada (Chairman), Azmi Nabulsi (Co-Founder), David Socks (Co-Founder), Roger Ulrich (Chief Scientific Officer)
Key Metrics
Current Price
$7.25
Market Cap
$577M
Float
65.3M
Shares Outstanding
80.9M
P/E (Forward)
6.60
Price/Sales (TTM)
2.41
vs. Analyst Target
+182.1% to analyst PT
Profit Margin
-41.34%
Operating Margin (TTM)
-5.34%
Revenue (TTM)
$240M
Dividend Rate
None
Analyst Target Price
$20.45 (12 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$129M
-$300,000
-$124M
2021
N/A
-$144M
-$521,000
-$137M
2022
N/A
-$198M
-$620,000
-$170M
2023
$682,000
-$202M
$515,000
-$159M
2024
$55.3M
-$334M
$47.3M
-$262M
2025
$175M
-$221M
$153M
-$152M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$49.5M
-$30.0M
Dec 2025
$57.6M
-$21.1M
Mar 2026
$58.3M
-$30.4M
Jun 2026
$74.3M
-$17.6M
Ownership & Float
Insider Ownership
4.7%
Institutional Ownership
92.3%
Short Float
16.6%
% of All Funds Holding
1.85%
Number of Funds Holding
163
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$8.30
Near-term / short-term trend
Weekly
40-Week SMA
$10.84
Medium-term trend
Weekly
80-Week SMA
$10.59
Cyclical trend (business cycle)
Weekly
200-Week SMA
$10.52
Secular trend (multi-year)
Monthly
10-Month SMA
$10.18
Near-term monthly trend
Monthly
20-Month SMA
$10.22
Medium-term monthly trend
Monthly
40-Month SMA
$10.47
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$9.50
resistance
1.07x
0 months ago
$10.60
resistance
1.31x
2 months ago
$4.30
support
2.84x
15 months ago
$17.30
resistance
1.95x
22 months ago
Historical Earnings Reactions (28 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.92%
0.97%
71.43%
8.41%
-11.50%
1 Day
-0.36%
1.81%
53.57%
12.09%
-17.86%
1 Week
-0.53%
1.02%
50.00%
39.94%
-52.54%
2 Weeks
2.26%
3.93%
60.71%
77.71%
-49.51%
1 Month
4.18%
6.69%
66.67%
59.15%
-54.62%
Next earnings: October 29, 2026 (18 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-8.0%
42.9%
7
Feb
6.6%
57.1%
7
Mar
-11.9%
14.3%
7
Apr
4.7%
57.1%
7
May
-4.1%
42.9%
7
Jun
23.0%
71.4%
7
Jul
-0.6%
57.1%
7
Aug
14.4%
71.4%
7
Sep
-3.7%
28.6%
7
Oct
-4.0%
33.3%
6
Nov
-10.0%
42.9%
7
Dec
7.1%
71.4%
7
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.25%
48.9%
327
Tuesday
0.22%
48.5%
361
Wednesday
0.04%
51.5%
357
Thursday
-0.07%
46.9%
350
Friday
0.45%
46.6%
348
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 92.3%
Insider Transactions — Smart Summary
Total insider ownership: 4.7%
Founder-led management: Tadataka Yamada (Chairman), Azmi Nabulsi (Co-Founder), David Socks (Co-Founder), Roger Ulrich (Chief Scientific Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Phathom Pharmaceuticals Inc
(PHAT) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.